Robova H, Rob L, Pluta M, Kacirek J, Halaska M, Strnad P, Schlegerova D
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Charles University Prague, 2nd Medical Faculty, Czech Republic.
Eur J Gynaecol Oncol. 2005;26(6):611-4.
The objective of this work was to assess proper management of squamous intraepithelial lesion (SIL) and microinvasive carcinoma during and after pregnancy, to assess risks of punch biopsy and conization in pregnancy and to assess regression, persistence and risk of progression with low-grade (L) and high-grade (H) SIL.
We carried out a prospective study of 167 pregnant women from our colposcopic unit who were referred to us for abnormal cytological findings between 1997 and 2002. The diagnosis of precancerosis was verified in all of the women by punch biopsy, suspect microinvasive carcinoma needle or LETZ conization up to the 20th week of pregnancy. All women were followed-up during the pregnancy and 24 months after their deliveries.
In 23 women with suspect early invasion we performed conization during the pregnancy (weeks 13-23). There were six cases (26.1%) of microinvasive carcinoma and 17 cases (73.9%) of HSIL. One pregnancy aborted two days after the conization. No other obstetrical complications were recorded and there were no premature deliveries. Sixty-two women with HSIL were only followed-up during their pregnancy. We observed complete regression of HSIL during the study in 14 patients (22.6%), regression to LSIL in 17 patients (27.4%), persistence in 25 patients (40.3%) and progression to microcarcinoma in six cases (9.7%). Eighty-two patients were followed up for LSIL. Complete regression of LSIL was observed during the study in 40 cases (48.8%), persistence in 24 cases (29.2%) and progression to HSIL in 18 cases (22.0%).
For LSIL and HSIL during pregnancy the above follow-up is a sufficient and safe protocol. Suspect microinvasive carcinoma should be treated by conization, which is a safe procedure until the 24th week of pregnancy.
本研究旨在评估妊娠期间及产后鳞状上皮内病变(SIL)和微浸润癌的恰当管理,评估妊娠期间穿刺活检和宫颈锥切术的风险,以及评估低级别(L)和高级别(H)SIL的消退、持续存在及进展风险。
我们对1997年至2002年间因细胞学检查异常而转诊至我院阴道镜科的167名孕妇进行了一项前瞻性研究。通过穿刺活检、可疑微浸润癌针吸活检或在妊娠20周前进行的大环状电切术(LETZ)对所有女性的癌前病变诊断进行了验证。所有女性在孕期及产后24个月进行随访。
在23例可疑早期浸润的女性中,我们在孕期(13 - 23周)进行了宫颈锥切术。其中有6例(26.1%)为微浸润癌,17例(73.9%)为高级别鳞状上皮内病变(HSIL)。1例妊娠在锥切术后两天流产。未记录到其他产科并发症,也没有早产情况。62例HSIL女性仅在孕期进行了随访。在研究期间,我们观察到14例患者(22.6%)的HSIL完全消退,17例患者(27.4%)的HSIL消退为低级别鳞状上皮内病变(LSIL),25例患者(40.3%)持续存在,6例患者(9.7%)进展为微癌。82例LSIL患者进行了随访。在研究期间,观察到40例患者(48.8%)的LSIL完全消退,24例患者(29.2%)持续存在,18例患者(22.0%)进展为HSIL。
对于孕期的LSIL和HSIL,上述随访方案是充分且安全的。可疑微浸润癌应通过宫颈锥切术治疗,在妊娠24周前这是一种安全的手术方式。